FDA Peptide Tracker

BPC-157: live FDA regulatory status

Recovery peptide · RFK-14

The two signals

Plain-English verdict: amber.

Regulatory status: PCAC recommended · rulemaking pending.

These two never collapse into one. Removal from a list is not the same as legal-to-compound, and neither is the same as available.

Availability at Peptós.LIFE

Join waitlist

What BPC-157 is

A recovery peptide people take in hope of speeding the healing of tendon, joint, muscle, and gut lining.

The recovery peptide everyone's talking about, with loud buzz and thin human proof.

BPC-157 is the peptide the recovery world can't stop talking about. The interest is real; the evidence is early.

Why it sits in this category

BPC-157 is tracked under RFK-14. Its regulatory status is PCAC recommended · rulemaking pending — a separate signal from whether you can actually get it today. We never collapse the two.

A 15-amino-acid sequence derived from a protein in gastric juice; proposed to support angiogenesis and tissue repair signaling.

What it does — and what it does not do

What it does: Studied for soft-tissue and gut-lining repair support.

What it does not do: It is not a proven cure for any injury.

What would have to change

Next milestone on the regulatory path: FDA rulemaking decision — Projected 2027. A favorable advisory (PCAC) vote is a recommendation that leads to rulemaking — not FDA approval, not authorization to compound, and not availability.

Evidence grade

Evidence grade D — Animal and lab evidence; human trials still to come. animal-dominant, fewer than 30 humans, no placebo-controlled efficacy trials See our grading methodology for what each grade means.

What we still don't know: Fewer than 30 humans have been studied, with no placebo-controlled efficacy trials. Long-term safety is uncharacterized.

Regulatory timeline

BPC-157: common questions

Is BPC-157 legal in 2026?
Not yet. On July 23, 2026 the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted to recommend BPC-157 for the 503A Bulks List, against the FDA's own scientific staff. The tally is reported as 8–6–1; the FDA has posted no minutes, transcript or vote-results summary for this meeting, so every tally on this site is as reported by trade press. A PCAC recommendation is advisory: it is not FDA approval, not authorization to compound, and not availability. Placement on the 503A Bulks List requires the FDA to run a formal rulemaking — a proposed rule, a comment period, then a final rule — which realistically takes well over a year. Earliest legitimate access is 2027, and only if the FDA proceeds.
Can I get BPC-157 right now?
No. BPC-157 is waitlist-only at Peptós.LIFE and cannot be legitimately prescribed or compounded today. We will not sell what we cannot stand behind. Compounded medications are prepared for an individual patient and are not FDA-approved.
Did the July 2026 FDA vote make BPC-157 available?
No. The vote changed the regulatory picture, not your access. Our regulatory status for BPC-157 advanced to "PCAC recommended · rulemaking pending," and the plain-English verdict stayed the same, because a committee vote does not move whether a patient can actually get it. The two signals are held separately for exactly this reason.
What happens next for BPC-157?
The milestone that matters is whether the FDA opens rulemaking on the 503A Bulks List, and how fast. Our projection is a decision in 2027. Nothing about availability changes before that concludes.

PCAC is advisory: its Jul 2026 recommendation leads to rulemaking, not instant availability. A favorable advisory vote is a recommendation, not FDA approval or authorization to compound. Realistic earliest legitimate access is late 2026 into 2027. Reclassification is not the same as FDA approval. Compounded medications are not evaluated or approved by the FDA for safety, efficacy, or quality, where that applies, we say so, plainly.

Primary source: FDA source record

See the full status board or this molecule's knowledge-base monograph.

Embed this card on your site · free, CC BY 4.0, no key.

Last updated July 26, 2026 · Peptós.LIFE · Not medical advice.